Movatterモバイル変換


[0]ホーム

URL:


AR131133A1 - PEGYLATED BOVINE INTERFERON AND METHODS OF USE THEREOF - Google Patents

PEGYLATED BOVINE INTERFERON AND METHODS OF USE THEREOF

Info

Publication number
AR131133A1
AR131133A1ARP230103138AARP230103138AAR131133A1AR 131133 A1AR131133 A1AR 131133A1AR P230103138 AARP230103138 AAR P230103138AAR P230103138 AARP230103138 AAR P230103138AAR 131133 A1AR131133 A1AR 131133A1
Authority
AR
Argentina
Prior art keywords
protein
amino acid
boifnl3
seq
conjugated
Prior art date
Application number
ARP230103138A
Other languages
Spanish (es)
Inventor
Nickolas Knudsen
Peter CANNING
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx IncfiledCriticalAmbrx Inc
Publication of AR131133A1publicationCriticalpatent/AR131133A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

Se describe una proteína conjugada de acción prolongada que comprende una proteína l-3 de interferón bovino conjugada con una fracción de polímero soluble en agua a través de un aminoácido no codificado naturalmente en la proteína. También se describen métodos de protección de mamíferos rumiantes contra la fiebre aftosa o la enfermedad respiratoria bovina mediante la administración de la proteína conjugada de acción prolongada. También se describen variantes de la proteína interferón l-3 bovina y variantes que contienen aminoácidos codificados de forma no natural adecuados para la conjugación con sustancias capaces de prolongar la vida media de eliminación de la proteína interferón l-3 bovina, como polímeros solubles en agua. Reivindicación 1: Una proteína conjugada que comprende: una proteína manipulada de interferón l3 bovino (boIFNl3) que tiene una secuencia de aminoácidos que comprende un aminoácido no natural; y un polímero soluble en agua; en donde el polímero soluble en agua se conjuga con la proteína boIFNl3 de ingeniería. Reivindicación 50: Una composición farmacéutica que comprende una proteína conjugada de acuerdo con cualquiera de las reivindicaciones 1 a 49 y un excipiente o vehículo farmacéuticamente aceptable. Reivindicación 51: Una proteína de interferón l3 bovino modificado (boIFNl3) que tiene una secuencia de aminoácidos que comparte al menos un 90% de identidad con SEQ ID Nº 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 o 13, y que comparte menos del 100% de identidad con SEQ ID Nº 1, y opcionalmente en donde la proteína boIFNl3 comprende además una metionina N-terminal; y donde: la secuencia de aminoácidos de la proteína boIFNl3 comprende un aminoácido no natural; o la secuencia de aminoácidos de la proteína boIFNl3 no comprende un aminoácido no natural. Reivindicación 66: Un ácido nucleico que tiene la secuencia de nucleótidos de SEQ ID Nº 27. Reivindicación 67: Un vector que comprende un ácido nucleico que codifica una cualquiera de las SEQ ID Nº 2 a 24. Reivindicación 68: Un vector que comprende un ácido nucleico que codifica SEQ ID Nº 5. Reivindicación 69: Un vector que comprende un ácido nucleico que codifica SEQ ID Nº 18. Reivindicación 70: Un vector que comprende un ácido nucleico que codifica SEQ ID Nº 19. Reivindicación 71: Una proteína de interferón l3 bovino (boIFNl3) modificada que tiene una secuencia de aminoácidos que comprende un aminoácido no natural; en donde la secuencia de aminoácidos de la proteína boIFNl3 diseñada: a) comparte al menos el 90% de identidad con SEQ ID Nº 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 o 24, o b) comparte al menos un 90% de identidad con SEQ ID Nº 14, 15, 16, 17, 18, 20, 21, 22, 23 o 24, y en donde la proteína boIFNl3 comprende además una metionina N-terminal.A long-acting conjugated protein is described comprising a bovine interferon l-3 protein conjugated to a water-soluble polymer moiety via an amino acid not naturally encoded in the protein. Also described are methods of protecting ruminant mammals against foot-and-mouth disease or bovine respiratory disease by administration of the long-acting conjugated protein. Also described are variants of the bovine interferon l-3 protein and variants containing non-naturally encoded amino acids suitable for conjugation to substances capable of prolonging the elimination half-life of the bovine interferon l-3 protein, such as water-soluble polymers. Claim 1: A conjugated protein comprising: an engineered bovine interferon l3 (boIFNl3) protein having an amino acid sequence comprising a non-naturally encoded amino acid; and a water-soluble polymer; wherein the water-soluble polymer is conjugated to the engineered boIFNl3 protein. Claim 50: A pharmaceutical composition comprising a conjugated protein according to any one of claims 1 to 49 and a pharmaceutically acceptable excipient or carrier. Claim 51: A modified bovine interferon l3 (boIFNl3) protein having an amino acid sequence that shares at least 90% identity with SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13, and that shares less than 100% identity with SEQ ID NO: 1, and optionally wherein the boIFNl3 protein further comprises an N-terminal methionine; and wherein: the amino acid sequence of the boIFNl3 protein comprises a non-naturally occurring amino acid; or the amino acid sequence of the boIFNl3 protein does not comprise a non-naturally occurring amino acid. Claim 66: A nucleic acid having the nucleotide sequence of SEQ ID NO: 27. Claim 67: A vector comprising a nucleic acid encoding any one of SEQ ID NO: 2 to 24. Claim 68: A vector comprising a nucleic acid encoding SEQ ID NO: 5. Claim 69: A vector comprising a nucleic acid encoding SEQ ID NO: 18. Claim 70: A vector comprising a nucleic acid encoding SEQ ID NO: 19. Claim 71: A modified bovine interferon l3 (boIFNl3) protein having an amino acid sequence comprising a non-naturally occurring amino acid; wherein the amino acid sequence of the designed boIFNl3 protein: a) shares at least 90% identity with SEQ ID No. 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24, or b) shares at least 90% identity with SEQ ID No. 14, 15, 16, 17, 18, 20, 21, 22, 23 or 24, and wherein the boIFNl3 protein further comprises an N-terminal methionine.

ARP230103138A2023-05-242023-11-22 PEGYLATED BOVINE INTERFERON AND METHODS OF USE THEREOFAR131133A1 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US202363504133P2023-05-242023-05-24

Publications (1)

Publication NumberPublication Date
AR131133A1true AR131133A1 (en)2025-02-19

Family

ID=88975494

Family Applications (1)

Application NumberTitlePriority DateFiling Date
ARP230103138AAR131133A1 (en)2023-05-242023-11-22 PEGYLATED BOVINE INTERFERON AND METHODS OF USE THEREOF

Country Status (2)

CountryLink
AR (1)AR131133A1 (en)
WO (1)WO2024241086A1 (en)

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4820352A (en)1983-01-101989-04-11Bausch & Lomb IncorporatedCleaning and conditioning solutions for contact lenses and methods of use
US5252714A (en)1990-11-281993-10-12The University Of Alabama In HuntsvillePreparation and use of polyethylene glycol propionaldehyde
US5446090A (en)1993-11-121995-08-29Shearwater Polymers, Inc.Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US7144574B2 (en)1999-08-272006-12-05Maxygen ApsInterferon β variants and conjugates
AU2001238595A1 (en)2000-02-222001-09-03Shearwater CorporationN-maleimidyl polymer derivatives
DE10112825A1 (en)2001-03-162002-10-02Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
JP2004537984A (en)2001-04-192004-12-24ザ スクリップス リサーチ インスティテュート Methods and compositions for producing orthogonal tRNA-aminoacyl tRNA synthetase pairs
DE10207072A1 (en)2002-02-202003-08-28Supramol Parenteral ColloidsNew N-(haloacetylaminoalkyl) amides of starch carboxylic acids, useful as modifying agents for drugs containing thiol groups, e.g. to increase solubility or plasma half-life or reduce antigenicity
RU2326891C2 (en)2002-09-112008-06-20Фрезениус Каби Дойчланд ГмбхHydroxyalkyl starch derivatives
JP4444113B2 (en)2002-10-162010-03-31ザ スクリップス リサーチ インスティテュート Method for site-specific protein incorporation of keto amino acids
WO2005007870A2 (en)2003-07-072005-01-27The Scripps Research InstituteCOMPOSITIONS OF ORTHOGONAL LEUCYL-tRNA AND AMINOACYL-tRNA SYNTHETASE PAIRS AND USES THEREOF
BRPI0412272A (en)2003-07-072006-09-05Scripps Research Inst orthogonal lysyl-trna and aminoacyl-trna synthetase pair compositions and uses thereof
EP1658366A4 (en)2003-07-072006-08-09Scripps Research Inst ORTHOGONAL PAIR COMPOSITIONS OF GLUTAMYL-ARNT AND AMINOACYL-ARNT SYNTHETASES AND USES THEREOF
WO2005074650A2 (en)2004-02-022005-08-18Ambrx, Inc.Modified human four helical bundle polypeptides and their uses
WO2005092369A2 (en)2004-03-112005-10-06Fresenius Kabi Deutschland GmbhConjugates of hydroxyethyl starch and erythropoietin
KR101186821B1 (en)2004-03-112012-09-28프레제니우스 카비 도이치란트 게엠베하Conjugates of Hydroxyalkyl Starch and A Protein, Prepared by Reductive Amination
US20060121073A1 (en)2004-07-122006-06-08Sandhya GoyalTopical gel formulation comprising insecticide and its preparation thereof
DK1812031T3 (en)2004-11-012015-09-14Univ CaliforniaCompositions and methods for the modification of biomolecules
EP1836298B1 (en)2004-12-222012-01-18Ambrx, Inc.COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
US7385028B2 (en)2004-12-222008-06-10Ambrx, IncDerivatization of non-natural amino acids and polypeptides
WO2007012033A2 (en)*2005-07-202007-01-25Zymogenetics, Inc.Il28 and il29 truncated cysteine mutants and antiviral methods of using same
AU2005335491B2 (en)2005-08-182010-11-25Ambrx, Inc.Compositions of tRNA and uses thereof
ES2547554T3 (en)2005-11-162015-10-07Ambrx, Inc. Methods and compositions comprising unnatural amino acids
CA2882445A1 (en)2005-12-142007-06-21Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2632832A1 (en)2005-12-302007-07-12Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1974025A4 (en)2006-01-192009-03-11Ambrx IncNon-natural amino acid polypeptides having modulated immunogenicity
CN101578264A (en)2006-12-182009-11-11Ambrx公司Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2009007001A (en)2006-12-282009-07-10Ambrx IncPhenazine and quinoxaline substituted amino acids and polypeptides.
ES2654387T3 (en)2008-07-232018-02-13Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
TR201802361T4 (en)2008-09-262018-03-21Ambrx Inc Microorganisms and vaccines dependent on unnatural amino acid replication.
US8906384B2 (en)2010-12-222014-12-09The United States Of America As Represented By The Secretary Of AgricultureAntiviral activity of bovine type III interferon against foot-and-mouth disease virus
JP5773382B2 (en)2010-12-292015-09-02株式会社Sumco Silica glass crucible and method for producing the same
CN110078788B (en)2011-05-272021-08-06Ambrx 公司Dolastatin derivatives containing unnatural amino acid linkages
DK2714685T3 (en)2011-05-272017-01-09Ambrx IncFORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
NZ713941A (en)2012-06-072017-02-24Ambrx IncProstate-specific membrane antigen antibody drug conjugates
WO2015153761A2 (en)2014-04-022015-10-08University Of RochesterMacrocyclic peptidomimetics for alpha-helix mimicry
CA3028683A1 (en)2016-06-202017-12-28Ambrx, Inc.Pegylated porcine interferon and methods of use thereof
KR20190062490A (en)*2016-09-302019-06-05더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Type III mutant interferon and < RTI ID = 0.0 >
HUE067136T2 (en)2017-06-022024-10-28Ambrx IncMethods and compositions for promoting non-natural amino acid-containing protein production
CN110272479B (en)*2018-03-142023-02-28江苏科技大学Cattle lambda 3 interferon mutant and preparation method and application thereof
US20220275041A1 (en)*2018-08-232022-09-01Exalt Therapeutics, LlcModified ifnl3 polypeptides comprising a pharmacokinetic enhancing moiety and their uses

Also Published As

Publication numberPublication date
WO2024241086A1 (en)2024-11-28

Similar Documents

PublicationPublication DateTitle
KR102314231B1 (en)Composition for treating prostate cancer
EP3484445B1 (en)Formulation for administration of rna
PE20071063A1 (en) STABLE PROTEIN FORMULATIONS
KR20030043993A (en)Vaccine composition
CL2019003409A1 (en) Isolated tumor associated peptide (tumap); nucleic acid; expression vector; recombinant host cell comprising the peptide; method of producing the peptide; use to prepare a rare useful drug to treat cancer; pharmaceutical kit. (divisional request 201702407)
ATE103297T1 (en) PEPTIDE, IMMUNOGENIC COMPOSITION AND VACCINE OR MEDICINAL PREPARATION, A METHOD OF IMMUNIZING A MAMMAL AGAINST LHRH AND METHOD OF IMPROVING MEA.
CA2692358A1 (en)Recombinant human interferon-like proteins
TWI642444B (en)Sugar chain added linker, compound comprising sugar chain added linker moiety and physiological active substance moiety, or salt thereof, and method for manufacturing thereof
AR123788A1 (en) FUSION PROTEINS INCLUDING SULFOGLUCOSAMINE SULFOHYDROLASE ENZYMES AND METHODS THEREOF
AR035077A1 (en) VARIOUS NEUBLASTIN POLYPEPTIDES, FUSION PROTEINS, NUCLEIC ACIDS, VECTORS, HOSPED CELLS, METHODS TO PRODUCE SUCH POLYPEPTIDES, DIMERES, CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND USE OF THESE MEDICINES
US7297676B2 (en)Thymosin alpha 1 peptide/polymer conjugates
CA2748392C (en)Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods)
AR131133A1 (en) PEGYLATED BOVINE INTERFERON AND METHODS OF USE THEREOF
NZ264218A (en)Storage stable aqueous composition of alpha-interferon
CN101671390B (en)Human interferon alpha derivatives and preparation and use of pegylated products thereof
AR014884A1 (en) USE OF AN IMMUNOGENIC ANGIOTENSIN CONJUGATE AND PHARMACEUTICAL COMPOSITION
CA2284548A1 (en)The use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of tumor necrosis factor (tnf)
AR127860A2 (en) FORMULATIONS OF THERAPEUTIC PEPTIDES RECEPTOR AGONISTS (GLP-1) / GLUCAGON
EP3166406B1 (en)Cytokine-chitosan bioconjugates and methods of using the same
CN115286700B (en)Analgesic polypeptide with plasma stability
US20240189414A1 (en)Engineered heartland virus mrna vaccine
ATE376836T1 (en) MUCIN PEPTIDE WITH IMMUNE-BOOSTING PROPERTIES
WO2025109155A1 (en)Interleukin variant
KR101919314B1 (en)A vaccine composition for Foot-and-Mouth Disease virus
AR123724A1 (en) COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19

[8]ページ先頭

©2009-2025 Movatter.jp